Edge Therapeutics, Inc. (NASDAQ:EDGE) Files An 8-K Results of Operations and Financial Condition
Item 2.02
|
Results of Operations and Financial Condition
|
announcing its financial results for the three months and full
year ended December 31, 2016. A copy of that press release and
the financial schedules attached thereto is furnished herewith as
Exhibit 99.1 to this Current Report on Form 8-K.
information set forth in this Current Report on Form 8-K is
deemed to be furnished and shall not be deemed to be filed for
purposes of the Securities Exchange Act of 1934, as amended (the
Exchange Act). The information in this Item 2.02, as well as
Exhibit 99.1, shall not be deemed incorporated by reference into
any filing under the Securities Act of 1933, as amended, or the
Exchange Act regardless of any general incorporation language in
such filing.
| Item 9.01. |
Financial Statements and Exhibits
|
|
Exhibit
Number
|
Description
|
|
99.1
|
Press release dated March 2, 2017 announcing financial
results for the three months and full year ended December 31, 2016. |
About Edge Therapeutics, Inc. (NASDAQ:EDGE)
Edge Therapeutics, Inc. is a clinical-stage biotechnology company that discovers, develops and seeks to commercialize, hospital-based therapies capable of transforming treatment paradigms in the management of life-threatening neurological and other conditions. Edge is evaluating EG-1962, its lead product candidate, in the Phase 3 NEWTON 2 study in adult patients with aneurysmal subarachnoid hemorrhage (aSAH). This study will evaluate EG-1962’s ability to improve patient outcomes versus standard of care oral nimodipine after an aSAH resulting from a ruptured brain aneurysm. Edge’s product candidates utilize Precisa, a platform with a approach that seeks to enable targeted and sustained drug exposure at the site of injury, while potentially avoiding off-target side effects associated with systemic delivery. Edge is also using its Precisa development platform to develop additional product candidates targeting other acute, serious conditions where limited or no current therapies exist. Edge Therapeutics, Inc. (NASDAQ:EDGE) Recent Trading Information
Edge Therapeutics, Inc. (NASDAQ:EDGE) closed its last trading session up +0.04 at 9.81 with 72,718 shares trading hands.
